ERBB2 and breast cancer: Previous study has reported that concurrent antibiotic use during neoadjuvant pembrolizumab therapy in HER2-negative early-stage breast cancer is associated with increased residual cancer burden, suggesting a potential adverse effect of microbial dysbiosis (30).